Clinical trials: Tobacco Smoking Behavior
Smoking
Characterization of Nicotine Exposure and Urge-to-Smoke Following Use of Electronic and Conventional Cigarettes
This trial was the initial characterization of the blu™ products being studied, with the purpose of gaining an understanding of the exposure to nicotine and craving reduction attained following use of blu™ e-cigarettes by adult…
- Trial name
- NCT02210754
- Testing
- blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin vehicle), blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin/PG vehicle), blu™ Magnificent Menthol rechargeable (2.4% nicotine, glycerin vehicle)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Lorillard Tobacco Company
Smoking Cessation
Efficacy and Safety of Βeta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction
To test the hypothesis that treatment with the inverse agonist nadolol will improve smoking cessation in patients with chronic cough associated with long-term smoking, with or without airflow obstruction, including those with…
- Trial name
- NCT01825122
- Testing
- Nadolol
- Where
- 4 sites in United States
- Volunteers
- 155 people
- Sponsor
- Invion, Inc.
Smoking Cessation
A Multi-National Study To Assess How Effective And Safe The Smoking Cessation Medicine Varenicline Is In Smokers Who Have Already Tried Varenicline In The Past As A Prescription Medicine From Their Usual Healthcare Provider
The main purpose of this study is to compare the effectiveness and safety of the re-treatment of smokers with varenicline with placebo for smoking cessation during the last 4 weeks of a 12 week course of treatment.
- Trial name
- NCT01244061
- Testing
- Varenicline
- Where
- 37 sites in United States, Australia and 6 more
- Volunteers
- 498 people
- Sponsor
- Pfizer
Smoking Cessation
12 Week Evaluation of the Safety and Efficacy of 4 Dosing Strategies of CP-526,555 and Placebo for Smoking Cessation.
The purpose of the study is to measure the safety and efficacy of four dosing strategies of CP-526,555 for 12 weeks compared with placebo for smoking cessation.
- Trial name
- NCT00150254
- Testing
- CP-526,555 (varenicline)
- Where
- 13 sites in United States
- Volunteers
- 625 people
- Sponsor
- Pfizer
Smoking
Comparison of Nicotine Plasma Concentrations and Subjective Effects for Three Electronic Cigarettes vs Combustible Cigarettes and Nicotine Gum
The purpose of this study is to measure plasma nicotine uptake parameters, physiological measures, and subjective effect measures in smokers during and following a single ad libitum use of three electronic cigarettes versus…
- Trial name
- NCT02269514
- Testing
- Own Brand Cigarette, Electronic Cigarette #1, Electronic Cigarette #2
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- R.J. Reynolds Vapor Company
Tobacco Smoking, Tobacco Use
Room Air Levels of Harmful and Potentially Harmful Constituents After Heated Tobacco Product Use and Cigarettes
This study is designed to assess and characterize levels of selected harmful and potentially harmful constituents (HPHCs) and other endpoints of interest in an environmental chamber (EC) after ad libitum use of Ploom® heated…
- Trial name
- NCT06476405
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Altria Client Services LLC
Smoking Cessation
Varenicline Observational Investigation In The Cessation of Smoking
The purpose of this study is to determine the safety and efficacy of varenicline in the real-world environment of smokers attending primary care in routine clinical practice with the addition of being offered behavioral support…
- Trial name
- CHOICES (NCT00669240)
- Testing
- Varenicline
- Where
- 52 sites in Belgium, Greece and 2 more
- Volunteers
- 567 people
- Sponsor
- Pfizer
Thromboangiitis Obliterans (Buerger's Disease)
A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers
This study is a first-in-human clinical trial of drug ATI-1013, in healthy adult cigarette smokers. The main questions it aims to answer are to learn about the safety of drug ATI-1013, how long drug ATI-1013 remains within the…
- Trial name
- NCT07215923
- Testing
- ATI-1013 (0.2 g), ATI-1013 (0.8 g), ATI-1013 (3.2 g)
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Antidote Therapeutics, Inc
Smoking Cessation
A Single Dose-escalation Study of Cytisine in Adult Smokers
The objectives of this study are: 1. To assess the tolerability and safety of cytisine as a single oral dose. 2. To define the Cmax levels associated to the occurrence of dose-limiting adverse events.
- Trial name
- NCT03848208
- Testing
- cytisine
- Where
- Portugal
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Achieve Life Sciences
Nicotine Addiction, Cigarette Smoking
Abuse Liability of Reduced Nicotine Content Cigarettes in the Context of Concurrent E-Cigarette Use
Three hundred-twenty (320) adult smokers of menthol or non-menthol combustible cigarettes will be recruited and randomly assigned to one of five groups (n=64/group), who will be asked to switch for 12 weeks to ad libitum use of…
- Trial name
- DUAL (NCT02870218)
- Testing
- Smoking research cigarettes with e-cigarette, Nicotine discrimination thresholds
- Where
- 2 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Rose Research Center, LLC
Smoking
In It To Quit: Commitment Contracts for Smoking Cessation
This study aims to examine whether a combination of positive and negative commitment devices is effective at inducing long-term smoking cessation in smokers from a low-to-moderate income background.
- Trial name
- I2Q (NCT02596061)
- Testing
- Deposit Contract, Incentives
- Where
- United States
- Volunteers
- 311 people, healthy volunteers welcome
- Sponsor
- Community Health Center, Inc.
Smoking, Tobacco Use
CSD190301: A Study to Assess Elements of Abuse Liability for Two Dissolvable Nicotine Lozenge Tobacco Products
This is a two-arm, single use, single-center, randomized, 10-sequence per arm, open-label, crossover pharmacokinetic/pharmacodynamic (PK/PD) study, designed to evaluate elements of abuse liability (AL) including subjective…
- Conditions
- Smoking, Tobacco Use, Tobacco Smoking
- Trial name
- NCT04167384
- Testing
- Product A, Product B, Product C
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Nicotine Replacement Therapy
A Study of Blood Levels of Nicotine Following an Electronic Cigarette
The purpose of this study is to assess the amount of nicotine that is absorbed into the blood stream following the use of a new Electronic Cigarette device called the CN electronic cigarette.
- Trial name
- NCT02794220
- Testing
- CN electronic cigarette 10 mg, CN electronic cigarette 15 mg, Nicorette Inhalator 15 mg
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Simbec Research
Smoking
Investigate the Exposure to Selected Smoke Constituents in Smokers Switching to Distillation Based Smoking Article
The overall purpose of this clinical study conducted in confinement under well-defined conditions is to obtain initial data on the levels of human body exposure to selected smoked constituents of the SMAR cigarette.
- Trial name
- NCT00812279
- Testing
- Distillation based smoking article (SMAR cigarette), conventional cigarette, smoking cessation
- Where
- Poland
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Smoking Cessation
Study of a Smartphone-Based Switch Program
Prospective, open label, single center clinical study enrolling up to 120 participants to evaluate the Pivot cigarette smoking cessation program in adult smokers, previously unable to quit, who also use other smoke-free nicotine…
- Trial name
- NCT06544772
- Testing
- Pivot cigarette smoking cessation program
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Pivot Health Technologies Inc.
Smoking
A Study of the Efficacy and Safety of Varenicline in Japanese Smokers Motivated to Quit Smoking
The purpose of this study is to evaluate the efficacy and safety of varenicline in Japanese smokers. Efficacy is evaluated by continuous quit rate and withdrawal symptoms of smokers.
- Trial name
- NCT00635401
- Testing
- Varenicline
- Where
- 8 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Pfizer
Smoking, Tobacco
CSD201204 An Actual Use Study of P12 Electronic Nicotine Delivery System Among U.S. Adult Smokers
The purpose of this Actual Use Study (AUS) is to investigate how United States (US) adult tobacco consumers 21 to 60 years of age, inclusive, who are regular smokers (≥5 cigarettes/day on at least 20 of the past 30 days) will use…
- Trial name
- NCT05960305
- Testing
- P1213416, P1213422, P1213716
- Where
- 12 sites in United States
- Volunteers
- 1,845 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Smoking Cessation
Assessment of Safety and Efficacy of Varenicline in Patients That Wish to Stop Smoking
The primary objective of this protocol is to evaluate 12 weeks of treatment of varenicline compared to placebo for smoking cessation.
- Trial name
- NCT00594204
- Testing
- varenicline tartrate (CP-526, 555-18)
- Where
- 42 sites in Brazil, Colombia and 9 more
- Volunteers
- 593 people
- Sponsor
- Pfizer
Smoking
Efficacy and Safety of Dianicline Versus Placebo as an Aid to Smoking Cessation
The primary objective is to demonstrate the efficacy of dianicline as an aid to smoking cessation in cigarette smokers. The main secondary objectives are: to assess the craving for cigarettes, nicotine withdrawal symptoms and the…
- Trial name
- EURODIAN (NCT00356967)
- Testing
- dianicline
- Where
- 6 sites in Belgium, Denmark and 4 more
- Volunteers
- 602 people
- Sponsor
- Sanofi
Smoking Cessation
Nicotine Lozenge Bioequivalence Study
To compare the bio equivalence of new nicotine lozenge formulation with the reference nicotine lozenge so as to deliver the same nicotine blood profile.
- Trial name
- NCT01536704
- Testing
- Nicotine (2 mg), Nicotine (4 mg)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline